We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neur... Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). Show more
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD PR Newswire ROCKVILLE, Md., March 28, 2024 A single ABBV-RGX-314 gene...
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days PR Newswire ROCKVILLE, Md., March 27, 2024 ROCKVILLE, Md., March 27, 2024 /PRNewswire/ -- REGENXBIO Inc...
REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., March 11, 2024 ROCKVILLE, Md., March 11, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced...
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants PR Newswire ROCKVILLE, Md., March 6, 2024 ROCKVILLE, Md., March 6, 2024 /PRNewswire/ -- REGENXBIO...
REGENXBIO Announces Proposed Public Offering of Common Stock PR Newswire ROCKVILLE, Md., March 6, 2024 ROCKVILLE, Md., March 6, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.33 | -17.5078864353 | 19.02 | 19.38 | 15.32 | 430751 | 17.28021388 | CS |
4 | -6.8 | -30.2356602935 | 22.49 | 22.84 | 15.32 | 441596 | 19.53154064 | CS |
12 | 2.26 | 16.8279970216 | 13.43 | 28.8 | 11.83 | 768729 | 19.41113885 | CS |
26 | -0.37 | -2.30386052304 | 16.06 | 28.8 | 11.83 | 647922 | 18.36732863 | CS |
52 | -3 | -16.051364366 | 18.69 | 28.8 | 11.83 | 510581 | 18.39297565 | CS |
156 | -19.14 | -54.9526270457 | 34.83 | 46.46 | 11.83 | 432515 | 24.71965295 | CS |
260 | -34.37 | -68.657610867 | 50.06 | 55.23 | 11.83 | 443827 | 30.95630941 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions